Brainstorm Cell Therapeutics Stock Price and Value Analysis

Brainstorm Cell Therapeutics (NasdaqCM:BCLI) in our automated value investing analysis, with the cash flow history and price comparison below.

Key Facts

  • Ticker: BCLI (NasdaqCM)
  • Current price: $0.85
  • Sector: Unknown
  • Industry: Unknown

Advertisement helps keep Trendshare free for most readers.

Hold-time calculator

Estimate how long you need to hold Brainstorm Cell Therapeutics to reach your target.

Target type

BCLI Free Cash Flow Trend

Free Cash Flow trendline for BCLI
Free Cash Flow trendline for Brainstorm Cell Therapeutics

Hmm, we can't give any reliable projection for Brainstorm Cell Therapeutics's growth rate. The company either has too few years of historical data for us to examine, or it's in the habit of losing money.

None of this means it's a bad stock. Maybe it's new and growing quickly, or maybe it's turning things around. We can't say anything sensible about it, so we won't say it's obviously undervalued right now. Proceed at your own risk!

AdvantagesDisadvantagesNeutral
None.
  • This company is not making money.
  • This stock looks overpriced.
  • This company is less known than others.
  • This company has wild ups and downs.
  • This company pays no dividend.

Inside the BCLI Numbers

BCLI Price
(Brainstorm Cell Therapeutics stock price per share)
$0.85
[?] PE Ratio versus Sector 100% lower than other Unknown stocks
[?] PE Ratio versus Industry 100% lower than other Unknown stocks
[?] Free Cash Flow Jitter 73%

Insider Activity Summary

No open-market insider buys or sells are recorded for the last 12 months.

This stock has short interest! This means that people have shorted it.

Why does that matter? They've made a bet that price will decrease from where they bought it. Maybe there are financial problems, or maybe there's a value play.

As of the latest analysis, there are 566,390 shares shorted. With 13,320,540 shares available for purchase and an average trading volume over the past 10 trading days of 29,880, it would take at least 19.0 days for all of the short holders to cover their shorts.

What does this mean to you? At this volume, it'll take more than two trading weeks for shorts to cover. This may indicate a short squeeze play would work! If this stock has good fundamentals and it'll take a while for the short holders to cover, buying now could net you bigger short-term technical gains if and as the price rises.

Related guides: good annual rate of return · high-yield stocks · forecasting earnings growth

Free Cash Flow by Fiscal Year

Cash Conversion

Net income was negative in all 10 fiscal years from 2011 to 2020, so no ratio of operating cash flow to net income is shown. Operating cash flow totaled -$88.2 million over those years, against net income of -$108.9 million.

In 2020, net income was -$31.8 million and operating cash flow was -$35.2 million, so no ratio is shown for that year.

Fiscal yearNet income (USD millions)Operating cash flow (USD millions)Capital expenditures (USD millions)Operating cash flow / net income
2011 -3.9 -2.2 0.0 n/a
2012 -3.4 -2.9 0.1 n/a
2013 -4.9 -4.1 0.1 n/a
2014 -9.2 -4.5 0.2 n/a
2015 -8.5 -7.4 0.0 n/a
2016 -5.0 -5.9 0.1 n/a
2017 -5.0 -2.4 0.2 n/a
2018 -13.9 -12.4 0.4 n/a
2019 -23.3 -11.2 0.5 n/a
2020 -31.8 -35.2 0.4 n/a

Balance Sheet

In 2020, cash and equivalents were $37.8 million against total liabilities of $15.8 million, or 239.5% of total liabilities. Total liabilities include everything the company owes, not only borrowed money.

Total liabilities were 30.8% of total assets in 2020, compared with 45.8% in 2011, a decrease of 15.0 percentage points.

Stockholders equity was $35.5 million in 2020, compared with $1.5 million in 2011, a rise of 2283.3%.

Fiscal yearTotal assets (USD millions)Cash and equivalents (USD millions)Total liabilities (USD millions)Stockholders equity (USD millions)
2011 2.7 1.9 1.3 1.5
2012 5.1 1.3 1.2 4.0
2013 4.7 3.5 2.0 2.7
2014 9.9 4.3 3.2 6.7
2015 17.1 0.4 3.0 14.1
2016 10.8 0.5 0.9 9.9
2017 11.4 2.5 5.5 5.9
2018 11.2 0.9 6.2 5.0
2019 6.5 0.5 18.8 -12.2
2020 51.3 37.8 15.8 35.5

Price Versus Our Estimated Value

None of the 10 fiscal years we have for Brainstorm Cell Therapeutics under its current SEC filer shows positive free cash flow.

We do not estimate a fair value for Brainstorm Cell Therapeutics while its free cash flow growth is not positive, so there is no value comparison here.

Year-to-year variability in free cash flow is volatile, measured at 73%.

No dividend yield is recorded for Brainstorm Cell Therapeutics in our data.

Before you act on any of this, read what a margin of safety means and check the company's own filings.

SEC Filer History

Every fiscal year on this page is reported by one SEC filer, CIK 1137883.

Each figure on this page comes from that filer.

Risks to This Analysis

  • Free cash flow was negative in 10 of the 10 years we have.
  • Free cash flow is volatile from year to year, so the estimates depend heavily on which years are included.
  • We have no value estimate for this stock, so no price comparison is made.
  • These figures are automated calculations from SEC filings and the recent price. They may contain errors, and they do not reflect lawsuits, management changes, or other events the filings do not show.

Advertisement supports free stock analysis content.

Questions to Answer Before You Invest in BCLI

Does Brainstorm Cell Therapeutics have a coherent story? Does it have a plan to continue to make money? Is it worth your time? Only you can decide where to go from here. Our investment guide helps you ask the right questions, including how to buy stocks. Use these research links for more information.

Worked example: BCLI

This example shows how we apply the Trendshare checklist to BCLI: earnings power, cash generation, valuation, and margin of safety.

We check: business quality, free cash flow, P/E, and margin of safety.

  1. Step 1 — Snapshot

    • Price: 0.85
    • Market cap: $9.4M
    • EPS: -0.93
  2. Step 2 — Valuation checks

    • P/E: —
    • FCF yield: —
    • Date checked: Nov 18, 2026
  3. Step 3 — Margin of safety

    • Compare price to fair value and safety price.
    • Look for durable cash generation and reasonable leverage.
    • Decide if it passes your personal checklist.